TribLIVE

| Business


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

Merck: FDA reviewing tablet to eliminate allergy

By The Associated Press
Thursday, March 28, 2013, 12:01 a.m.
 

Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.

The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.

for three years.

The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.

 

 
 


Show commenting policy

Most-Read Business Headlines

  1. Balancing gas pipeline expansion, environmental unease a problem in Pennsylvania
  2. Symposiums to spotlight Pittsburgh’s role as an energy powerhouse
  3. Hospitals turn to technology to tear down language barriers with patients
  4. More companies embrace exchanges to curb health care costs
  5. Bayer to spin off plastics unit as separate company; employment to remain stable
  6. Chemical used for freshness leaves EU with little appetite for U.S. apples
  7. Mylan CEO Bresch sets sights on growth
  8. Getting into executive pipeline may require schmoozing
  9. MarksJarvis: Benefits, not just pay, hit the skids
  10. U.S. Steel shares jump on turnaround strategy
  11. Consol, Noble expect at least $325 million from partnership’s IPO
Subscribe today! Click here for our subscription offers.